文献速递脑血管病

氯吡格雷联合阿司匹林治疗小卒中或短暂性脑缺血发作的结局:CHANCE与POINT试验汇总分析

Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials.
PubMed 文献 · JAMA Neurol · 2019-01-01

该汇总分析纳入CHANCE和POINT两项随机试验的10 051例小卒中或高危TIA患者,比较氯吡格雷联合阿司匹林与单用阿司匹林的效果。结果显示双联抗血小板治疗降低90天内主要缺血事件风险(6.5% vs 9.1%;HR 0.70),获益主要集中于前21天,而大出血差异无统计学意义。

要点

  • 双联抗血小板治疗降低90天主要缺血事件风险,HR 0.70(95%CI 0.61-0.81)。
  • 获益主要在前21天(HR 0.66),第22至90天未见显著获益。
  • 大出血在双联组更常见但差异无统计学意义。

核心结论

  • 在小卒中或高危TIA患者中,氯吡格雷联合阿司匹林的获益似乎仅限于发病后前21天。

研究设计与样本

  • 汇总CHANCE和POINT两项随机临床试验的个体患者数据,共纳入10 051例患者(氯吡格雷-阿司匹林组5016例,对照组5035例),中位年龄63.2岁,男性60.8%,随访90天。

主要发现

  • 90天主要缺血事件在氯吡格雷-阿司匹林组为6.5%(328/5016),对照组为9.1%(458/5035),HR 0.70(95%CI 0.61-0.81),P < .001。
  • 前21天主要缺血事件在氯吡格雷-阿司匹林组为5.2%(263/5016),对照组为7.8%(391/5035),HR 0.66(95%CI 0.56-0.77),P < .001;第22至90天未见显著获益。
  • 大出血在氯吡格雷-阿司匹林组更常见,但差异无统计学意义。
  • 未观察到试验间或预设亚组间治疗结局的异质性证据。

临床怎么用

  • 对于小卒中或高危TIA患者,可考虑在发病后前21天内使用氯吡格雷联合阿司匹林以降低主要缺血事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dual antiplatelet therapy with clopidogrel and aspirin is effective for secondary prevention after minor ischemic stroke or transient ischemic attack (TIA). Uncertainties remained about the optimal duration of dual antiplatelet therapy for minor stroke or TIA. OBJECTIVE: To obtain precise estimates of efficacy and risk of dual antiplatelet therapy after minor ischemic stroke or TIA. DESIGN, SETTING, AND PARTICIPANTS: This analysis pooled individual patient-level data from 2 large-scale randomized clinical trials that evaluated clopidogrel-aspirin as a treatment to prevent stroke after a minor stroke or high-risk TIA. The Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) trial enrolled patients at 114 sites in China from October 1, 2009, to July 30, 2012. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial enrolled patients at 269 international sites from May 28, 2010, to December 19, 2017. Both were followed up for 90 days. Data analysis occurred from November 2018 to May 2019. INTERVENTIONS: In the 2 trials, patients with minor stroke or high-risk TIA were randomized to clopidogrel-aspirin or aspirin alone within 12 hours (POINT) or 24 hours (CHANCE) of symptom onset. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a major ischemic event (ischemic stroke, myocardial infarction, or death from ischemic vascular causes). The primary safety outcome was major hemorrhage. RESULTS: The study enrolled 5170 patients (CHANCE) and 4881 patients (POINT). Analysis included individual data from 10 051 patients (5016 in the clopidogrel-aspirin treatment group and 5035 in the control group) with a median age of 63.2 (interquartile range, 55.0-72.9) years; 6106 patients (60.8%) were male. Clopidogrel-aspirin treatment reduced the risk of major ischemic events at 90 days compared with aspirin alone (328 of 5016 [6.5%] vs 458 of 5035 [9.1%]; hazard ratio [HR], 0.70 [95% CI, 0.61-0.81]; P < .001), mainly within the first 21 days (263 of 5016 [5.2%] vs 391 of 5035 [7.8%]; HR, 0.66 [95% CI, 0.56-0.77]; P < .001), but not from day 22 to day 90. No evidence of heterogeneity of treatment outcome across trials or prespecified subgroups was observed. Major hemorrhages were more frequent in the clopidogrel-aspirin group, but the difference was nonsignificant. CONCLUSIONS AND RELEVANCE: In this analysis of the POINT and CHANCE trials, the benefit of dual antiplatelet therapy appeared to be confined to the first 21 days after minor ischemic stroke or high-risk TIA.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Pan Y, Elm JJ, Li H, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019. PMID: 31424481. doi:10.1001/jamaneurol.2019.2531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。